Literature DB >> 27141291

Ibogaine-associated cardiac arrest and death: case report and review of the literature.

Jessica A Meisner1, Susan R Wilcox2, Jeremy B Richards3.   

Abstract

A naturally occurring hallucinogenic plant alkaloid, ibogaine has been used as an adjuvant for opiate withdrawal for the past 50 years. In the setting of an escalating nationwide opiate epidemic, use of substances such as ibogaine may also increase. Therefore, familiarity with the mechanisms and potential adverse effects of ibogaine is important for clinicians. We present the case report of a man whose use of ibogaine resulted in cardiac arrest and death, complemented by a review of the literature regarding ibogaine's clinical effects. A 40-year-old man who used ibogaine for symptoms of heroin withdrawal suffered acute cardiac arrest leading to cerebral edema and brain death. His presentation was consistent with ibogaine-induced cardiotoxicity and ibogaine-induced cardiac arrest, and a review of the literature regarding the history, mechanisms, risks and clinical outcomes associated with ibogaine is presented. The case presented underscores the significant potential clinical risks of ibogaine. It is important the healthcare community be aware of the possible effects of ibogaine such that clinicians can provide informed counseling to their patients regarding the risks of attempting detoxification with ibogaine.

Entities:  

Keywords:  cardiac arrest; ibogaine; medication effects

Year:  2016        PMID: 27141291      PMCID: PMC4837967          DOI: 10.1177/2045125315626073

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  16 in total

Review 1.  Mania following use of ibogaine: A case series.

Authors:  Cole J Marta; Wesley C Ryan; Alex Kopelowicz; Ralph J Koek
Journal:  Am J Addict       Date:  2015-04-14

2.  Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'.

Authors:  Brian Vastag
Journal:  Science       Date:  2005-04-15       Impact factor: 47.728

3.  Long-QT syndrome induced by the antiaddiction drug ibogaine.

Authors:  Dianne W M Hoelen; Wilko Spiering; Gerlof D Valk
Journal:  N Engl J Med       Date:  2009-01-15       Impact factor: 91.245

4.  A case of death due to ibogaine use for heroin addiction: case report.

Authors:  Shwan Jalal; Edouard Daher; Raymond Hilu
Journal:  Am J Addict       Date:  2013 May-Jun

5.  Fatalities temporally associated with the ingestion of ibogaine.

Authors:  Kenneth R Alper; Marina Stajić; James R Gill
Journal:  J Forensic Sci       Date:  2012-01-23       Impact factor: 1.832

6.  Moving beyond misuse and diversion: the urgent need to consider the role of iatrogenic addiction in the current opioid epidemic.

Authors:  Gillian A Beauchamp; Erin L Winstanley; Shawn A Ryan; Michael S Lyons
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

7.  Treatment of acute opioid withdrawal with ibogaine.

Authors:  K R Alper; H S Lotsof; G M Frenken; D J Luciano; J Bastiaans
Journal:  Am J Addict       Date:  1999

Review 8.  Opioid epidemic in the United States.

Authors:  Laxmaiah Manchikanti; Standiford Helm; Bert Fellows; Jeffrey W Janata; Vidyasagar Pampati; Jay S Grider; Mark V Boswell
Journal:  Pain Physician       Date:  2012-07       Impact factor: 4.965

9.  Life-threatening complications of ibogaine: three case reports.

Authors:  F P Paling; L M Andrews; G D Valk; H J Blom
Journal:  Neth J Med       Date:  2012-11       Impact factor: 1.422

10.  Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: a study to assess the drug's cardiac ion channel profile.

Authors:  Xaver Koenig; Michael Kovar; Lena Rubi; Agnes K Mike; Peter Lukacs; Vaibhavkumar S Gawali; Hannes Todt; Karlheinz Hilber; Walter Sandtner
Journal:  Toxicol Appl Pharmacol       Date:  2013-05-22       Impact factor: 4.219

View more
  1 in total

Review 1.  The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).

Authors:  Genís Ona; Juliana Mendes Rocha; José Carlos Bouso; Jaime E C Hallak; Tre Borràs; Maria Teresa Colomina; Rafael G Dos Santos
Journal:  Psychopharmacology (Berl)       Date:  2021-08-18       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.